NVCR - NovoCure Ltd
IEX Last Trade
30.95
13.340 43.102%
Share volume: 0
Last Updated: Tue 24 Dec 2024 05:59:59 PM CET
Surgical and Medical Instrument Manufacturing :
50.37%
PREVIOUS CLOSE
CHG
CHG%
$17.61
13.34
75.75%
Fundamental analysis
27%
Profitability
25%
Dept financing
26%
Liquidity
75%
Performance
19%
Performance
5 Days
0.55%
1 Month
64.91%
3 Months
94.17%
6 Months
71.67%
1 Year
132.86%
2 Year
-57.58%
Key data
Stock price
$30.95
DAY RANGE
$17.61 - $30.11
52 WEEK RANGE
$12.19 - $34.13
52 WEEK CHANGE
$104.02
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/24/2024
Company detail
CEO: Asaf Danziger
Region: US
Website: novocure.com
Employees: 1,320
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Surgical and Medical Instrument Manufacturing
Sector: Manufacturing
Region: US
Website: novocure.com
Employees: 1,320
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Surgical and Medical Instrument Manufacturing
Sector: Manufacturing
NovoCure Limited engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma.
Recent news